Prolongation ventricular refractoriness class Ia antiarrhythmic drugs prevention ventricular tachycardia induction effects class la antiarrhythmic drugs procainamide quinidine right ventricular effective refractory period VERP intraventricular conduction time serial invasive electrophysiologic studies sustained monomorphic ventricular tachycardia VT patients remote myocardial infarction VT inducible extrastimuli basic drive basic cycle lengths right ventricular apex oral drug administration VT inducible group patients inducible group II protocol Class la drugs VERP groups drugs effective msec group msec group II basic cycle length msec Prolongation VERP msec positive predictive value prevention sustained VT induction patient group drugs VERP coupling intervals sustained VT induction control conditions attainable contrast conduction time ventricle surface QRS duration sinus rhythm right ventricular pacing efficacy msec vs msec cycle length msec presence similar plasma levels drug equivalent prolongation VERP groups results prolongation VERP oral procainamide correlates drug efficacy VT induction predictor drug effect achievement therapeutic plasma level 